| 梁梅兰,吴美景,王 微,陈菊梅,王文佳,丁秀秀.慢性阻塞性肺疾病稳定期患者血清VAP-1、MSP、SDF-1水平与肺功能、炎性因子及生活质量的关系研究[J].,2021,(16):3164-3169 |
| 慢性阻塞性肺疾病稳定期患者血清VAP-1、MSP、SDF-1水平与肺功能、炎性因子及生活质量的关系研究 |
| Relationship Study between Serum VAP-1, MSP, SDF-1 Levels and Pulmonary Function, Inflammatory Factors and Quality of Life in Patients with Stable Chronic Obstructive Pulmonary Disease |
| 投稿时间：2021-01-06 修订日期：2021-01-28 |
| DOI：10.13241/j.cnki.pmb.2021.16.034 |
| 中文关键词: 慢性阻塞性肺疾病 稳定期 血管黏附蛋白-1 巨噬细胞刺激蛋白 基质细胞衍生因子-1 肺功能 炎性因子 生活质量 |
| 英文关键词: Chronic obstructive pulmonary disease Stable Vascular adhesion protein-1 Macrophage stimulating protein Stromal cellderived factor-1 Pulmonary function Inflammatory factors Quality of life |
| 基金项目:海南省自然科学基金项目（20168340） |
|
| 摘要点击次数: 778 |
| 全文下载次数: 379 |
| 中文摘要: |
| 摘要 目的：探讨慢性阻塞性肺疾病（COPD）稳定期患者血清血管黏附蛋白-1（VAP-1）、巨噬细胞刺激蛋白（MSP）、基质细胞衍生因子-1（SDF-1）水平与肺功能、炎性因子及生活质量的关系。方法：选取我院2018年9月～2020年9月收治的COPD稳定期患者116例作为COPD组，选取同期于我院体检的健康志愿者100例作为对照组。比较两组血清VAP-1、MSP、SDF-1水平以及肺功能指标[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC、最大呼气流速（PEF）]、炎症因子[白介素-6（IL-6）、白介素-17（IL-17）、白介素-22（IL-22）、肿瘤坏死因子-α（TNF-α）]水平。根据COPD稳定期患者的严重程度，分成轻度组（n=53）、中度组（n=34）、重度组（n=29），比较三组上述各指标水平。采用COPD评估测试表（CAT）评估三组生活质量并进行比较，经Pearson线性相关分析血清VAP-1、MSP、SDF-1水平与肺功能、炎性因子及CAT评分的相关性。结果：COPD组血清VAP-1、MSP、SDF-1、IL-6、IL-17、IL-22及TNF-α水平均高于对照组，而FEV1、FVC、FEV1/FVC以及PEF低于对照组（P＜0.05）。轻度组血清VAP-1、MSP、SDF-1、IL-6、IL-17、IL-22、TNF-α水平及CAT评分较中度、重度组明显降低，且中度组低于重度组，而轻度组FEV1、FVC、FEV1/FVC、PEF较中度、重度组增高，且中度组高于重度组（P＜0.05）。Pearson线性相关分析提示，血清VAP-1、MSP、SDF-1水平与FEV1、FVC、FEV1/FVC、PEF呈负相关，三者与血清IL-6、IL-17、IL-22、TNF-α水平及CAT评分呈正相关（P＜0.05）。结论：COPD稳定期患者的血清VAP-1、MSP、SDF-1水平明显上调，且三者与患者的肺功能、炎症因子及生活质量密切相关，临床有望通过测定血清VAP-1、MSP、SDF-1水平，评估COPD稳定期患者病情进展情况。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum vascular adhesion protein-1 (VAP-1), macrophage stimulating protein (MSP), stromal cellderived factor-1 (SDF-1) levels and pulmonary function, inflammatory factors and quality of life in patients with stable chronic obstructive pulmonary disease (COPD). Methods: 116 patients with stable COPD in our hospital from September 2018 to September 2020 were selected as the COPD group, and 100 healthy volunteers who had physical examination in our hospital during the same period were selected as the control group. The serum VAP-1, MSP, SDF-1 levels, pulmonary function indexes [Forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, peak expiratory flow (PEF)], inflammatory factors [interleukin-6 (IL-6), interleukin-17 (IL-17), interleukin-22 (IL-22), tumor necrosis factor-α (TNF-α)] levels were compared between the two groups. According to the severity of patients with stable COPD, they were divided into mild group (n=53), moderate group (n=34) and severe group (n=29). The above indexes were compared among the three groups. The quality of life of the three groups was evaluated and compared by COPD assessment test (CAT), Pearson linear correlation analysis was used to analyze the correlation between serum VAP-1, MSP, SDF-1 levels and pulmonary function, inflammatory factors and CAT score. Results: The serum VAP-1, MSP, SDF-1, IL-6, IL-17, IL-22 and TNF-α levels in COPD group were higher than those in control group, while FEV1, FVC, FEV1/FVC and PEF were lower than those in control group (P<0.05). Serum VAP-1, MSP, SDF-1, IL-6, IL-17, IL-22, TNF-α levels and CAT score in the mild group were significantly lower than those in the moderate group and severe group, and the moderate group was lower than the severe group, while FEV1, FVC, FEV1/FVC, PEF in the mild group were higher than those in the moderate group and severe group, and the moderate group was higher than the severe group (P<0.05). Pearson linear correlation analysis indicated that serum VAP-1, MSP, SDF-1 levels were negatively correlated with FEV1, FVC, FEV1/FVC, PEF, and the three were negatively correlated with serum IL-6, IL-17, IL-22, TNF-α level and CAT score were positively correlated (P<0.05). Conclusion: The serum VAP-1, MSP and SDF-1 level in patients with stable COPD are significantly up-regulated, and the three are closely related to the patient's pulmonary function, inflammatory factors and quality of life. Clinically, it is expected that the determination of serum VAP-1, MSP and SDF-1 levels, so as to assess the progress of patients with stable COPD. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
